Platform will provide workload management with Platform LSF across Entelos' server farms and will enable distributed desktop processing with Platform LSF ActiveCluster, which harnesses unused desktop cycles to process compute-intensive tasks efficiently, complete workloads faster, and increase user productivity.
"We chose Platform's solution because we wanted a commercially supported, end-to-end package from a partner who has extensive experience in providing solutions to the life sciences community", stated Alex Bangs, CTO, Entelos. "Platform LSF ActiveCluster was a deciding factor; with ActiveCluster we can go beyond traditional distributed computing and expand our processing power by utilising idle desktops. As we plan to offer this technology to our pharmaceutical partners, this will provide as significant a benefit to them as it will to us."
The expert in predictive biosimulation for in silico drug discovery and development, Entelos partners with pharmaceutical and biotech organisations worldwide to develop effective new treatments for disease. With its patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease and uses them to rapidly simulate experiments on virtual patients which could take months or years to do in the lab or clinic. Each PhysioLab provides a framework for integrating data including genomic, proteomic, physiologic, and environmental information, in the context of a disease, with a focus on understanding and determining clinical responses to potential treatment.
"Entelos has a very exciting technology that can accelerate the discovery and development of new drugs and therapeutic interventions", stated Yury Rozenman, director, Life Sciences, Platform. "With Platform LSF and LSF ActiveCluster, Entelos has the scalability and additional compute power to do more analyses and computations, accelerating disease research for pharmaceutical companies. With Platform's solution, Entelos can represent more virtual patients and analyse them faster than ever before, speeding up the process for its research and its partners."
Entelos' in silico R&D increases productivity at every stage of drug discovery and development including lead generation, lead optimisation, and clinical development. Entelos is applying in silico R&D today to help its pharmaceutical partners identify and characterise novel pathways and genes; prioritise and evaluate targets and candidates; plan and optimise clinical trials and experiments; assess the clinical impact of therapeutic approaches on different patient populations; and relate genomic, proteomic, and in vitro data to clinical outcomes.
Entelos' patented PhysioLab technology provides a breakthrough platform for testing experiments and hypotheses in silico, predicting the results through simulation, and creating knowledge out of fragmented discovery and clinical data. Entelos provides integrated expertise in the metabolic, immunologic, and respiratory areas, and currently offers PhysioLab systems for asthma, obesity, diabetes, and adipocytes.
Platform LSF addresses the high-throughput computational requirements of modern life sciences computing environments by providing on demand access to valuable computing resources. From a single cluster of Linux compute farms, Microsoft Windows desktops or worldwide grids of distributed systems, Platform LSF delivers consistent performance and scalability in distributing applications and executing workload.
Platform LSF ActiveCluster adds distributed desktop processing to the LSF suite and allows enterprises to extend processing power by taking advantage of unused desktop cycles and creating "desktop clusters". When a PC is idle or underutilised, it contacts the Platform LSF ActiveCluster server, which dispatches a suitable distributed computing job. Once the desktop completes the task, it returns results to the server and is assigned a new task.
Life Sciences organisations around the globe are incorporating Platform's distributed computing solutions into the discovery process to maximise the productivity and potential of their existing technology investments. Platform seamlessly integrates with and distributes application workload, allowing scientists to exploit and analyse diverse types and sources of biological data in a shorter period of time, deliver more accurate results to reduce failure rates, and enable better decision-making earlier in the discovery process.
Recently, Platform announced that it is working with the French Myopathy Association (AFM) and IBM to power the "Decrypthon" project. You can read more about it in this VMW issue's article "Decrypthon" project harnesses virtual supercomputer power to understand the causes of genetic disease.